Enoch Cobbina, PhD

Director of Clinical Pharmacology
Syndax Pharmaceuticals, Inc.

Poster(s):

• 075: Population Pharmacokinetics of Trastuzumab Deruxtecan (T-DXd) in Subjects With HER2-mutant & HER2-overexpressing Non-Small Cell Lung Cancer (NSCLC)
  Sunday, September 8, 2024

  5:00 PM – 7:00 PM ET

• 138: Exposure-Response Analyses of Efficacy & Safety of Trastuzumab Deruxtecan to Inform Dosing Recommendation in HER2-mutant Non-Small Cell Lung Cancer
  Monday, September 9, 2024

  5:00 PM – 7:00 PM ET

• 157: Pharmacokinetics & Exposure-Response Analyses of Revumenib Support Dosing in a Broad Population of Patients With Relapsed/Refractory Acute Leukemias
  Monday, September 9, 2024

  5:00 PM – 7:00 PM ET